Moreover, SGLT2 inhibitors are known to have cardio- and renoprotective effects (60–62) and have the potential to improve systemic metabolism, thus possibly preventing respiratory failure and organ dysfunction associated with COVID-19. This evidence concerns the gene SLC5A2 and respiratory failure.